Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| UTHR | CLUSTER | bearish | 4/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $2.72M in UTHR stock over a 7-day window. The CEO's sales follo | Jul 22, 2026 |
| DYN | PRESS-RELEASE | bearish | 6/10 | Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, raising gro | Jul 21, 2026 |
| ACRV | PRESS-RELEASE | neutral | 3/10 | Acrivon Therapeutics announced presentations at the AACR D3 conference highlighting preclinical and early clinical data | Jul 21, 2026 |
| TLX | PRESS-RELEASE | bullish | 5/10 | Telix announced peer-reviewed publication of ProstACT SELECT Phase 1 results in Cancers, confirming that 68Ga-PSMA-PET i | Jul 21, 2026 |
| APLM | 6-K | neutral | 3/10 | Apollomics Inc. reported the resignation of two directors (Yi-An Chu and Dr. Chen-Huan Jan) and the appointment of Hung- | Jul 21, 2026 |
| GILD | ANALYST-DOWNGRADE | bearish | 4/10 | Leerink Partners double-downgraded Gilead Sciences from Outperform to Market Perform on July 21, slashing its price targ | Jul 21, 2026 |
| IMRN | 6-K | neutral | 2/10 | Immuron filed a 6-K announcing that CEO Steven Lydeamore will present at the TechKnow Invest Roadshow on July 27, 2026. | Jul 21, 2026 |
| CVKD | EFFECT | neutral | 2/10 | Cadrenal Therapeutics' S-3 shelf registration statement (File No. 333-297432) became effective on July 20, 2026, allowin | Jul 21, 2026 |
| ATHE | 6-K | neutral | 2/10 | Analysis based on filing metadata only, document content was unavailable. This 6-K report announces an application for q | Jul 21, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk reported weekly share repurchase transactions under its ongoing DKK 15 billion buyback program. Through 17 | Jul 21, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a 6-K announcing its CEO will participate in the BTIG Biotechnology Conference 2026, hosting | Jul 21, 2026 |
| IPHA | 6-K | mixed | 5/10 | Innate Pharma completed enrollment in the Phase 1 dose escalation study of IPH4502, a Nectin-4 ADC, with 76 patients enr | Jul 21, 2026 |
| NVS | 6-K | neutral | 4/10 | Novartis reported Q2 2026 net sales of $14.4B (+3% USD, +1% cc), with core operating income flat at $5.9B (0% cc). Net i | Jul 21, 2026 |
| OKYO | 6-K | bullish | 5/10 | OKYO Pharma's Chairman Gabriele Cerrone purchased 25,000 ordinary shares at $1.40/share through Panetta Partners Ltd, in | Jul 21, 2026 |
| TLX | 6-K | bullish | 6/10 | Telix Pharmaceuticals reported Q2 2026 revenue of US$247M, +21% YoY and +7% QoQ, driven by Precision Medicine (+30% YoY) | Jul 21, 2026 |
| ZEOX | 8-K | neutral | 2/10 | Zeo ScientifiX issued a press release highlighting its role in South Florida's regenerative medicine ecosystem, with ini | Jul 21, 2026 |
| VYNE | 8-K | neutral | 5/10 | VYNE Therapeutics filed an 8-K announcing a 1-for-50 reverse stock split and a $17.3 million special cash dividend ($0.4 | Jul 21, 2026 |
| ANNX | ANALYST-UPGRADE | bullish | 4/10 | Citizens initiated coverage of Annexon (ANNX) at Market Underperform with a $3 price target, implying 48% downside from | Jul 21, 2026 |
| CVKD | 8-K | neutral | 5/10 | Cadrenal Therapeutics announced a strategic realignment of its pipeline into a Cardiac Acute Critical Care Franchise and | Jul 21, 2026 |
| PRFX | 6-K | neutral | 2/10 | PRF Technologies announced its DeepSolar unit will showcase the GridFeed AI platform at Energy Trading Week Europe 2026 | Jul 21, 2026 |
| BGM | 20-F | bearish | 7/10 | BGM Group Ltd.'s FY2025 20-F reveals a deeply deteriorating financial picture: net loss widened to $20.2M from $1.5M, dr | Jul 21, 2026 |
| OKYO | 6-K | neutral | 2/10 | OKYO Pharma filed a 6-K announcing a corporate presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conf | Jul 21, 2026 |
| WLK | PRESS-RELEASE | neutral | 1/10 | Westlake Corporation announced it will host a conference call on August 4, 2026 to discuss its Q2 2026 results. | Jul 21, 2026 |
| RNTX | PRESS-RELEASE | neutral | 3/10 | Rein Therapeutics announced that its Phase 2 RENEW trial for inhaled LTI-03 in IPF is now open in Germany, completing th | Jul 21, 2026 |
| HELP | PRESS-RELEASE | neutral | 5/10 | Helus Pharma completed enrollment in the APPROACH Phase 3 pivotal study of HLP003 for Major Depressive Disorder (MDD) ah | Jul 21, 2026 |
| RZLT | PRESS-RELEASE | neutral | 2/10 | Rezolute announced management participation in the BTIG Virtual Biotechnology Conference on July 28-29, 2026. This is a | Jul 21, 2026 |
| PSTV | PRESS-RELEASE | neutral | 4/10 | Plus Therapeutics subsidiary CNSide Diagnostics signed a regional agreement with Medical Mutual covering ~1.2M members i | Jul 21, 2026 |
| TPST | PRESS-RELEASE | neutral | 5/10 | Tempest Therapeutics announced a strategic partnership with Hebei Senlang Biotechnology to develop TPST-4003, an in vivo | Jul 21, 2026 |
| INSM | ANALYST-UPGRADE | bullish | 4/10 | BMO Capital initiated coverage on INSM at Outperform with a $192 price target, implying 78.6% upside from the current $1 | Jul 21, 2026 |
| JUNS | PRESS-RELEASE | bullish | 7/10 | Jupiter Neurosciences licensed exclusive U.S. rights to ALA-002, an FDA-designated Novel Chemical Entity (non-racemic MD | Jul 21, 2026 |